Archive

Neovasc Announces FDA Approval of COSIRA-II Clinical Trial

Company on Schedule to Commence Trial Late This YearVANCOUVER and MINNEAPOLIS - (NewMediaWire) - September 16, 2021 - Neovasc Inc. (Neovasc or the Company) (Nasdaq, TSX: NVCN) announced today that it has received FDA approval for the Investigational Device Exemption (IDE) regarding the COSIRA-II IDE...

Read More

Neovasc Announces Submission of COSIRA-II Protocol Supplement to FDA

VANCOUVER and MINNEAPOLIS- (NewMediaWire) - August 17, 2021 - Neovasc Inc. (Neovasc or the Company) (Nasdaq, TSX: NVCN) announced today that it has filed a supplement to the COSIRA-II Investigational Device Exemption (IDE) Study with the U.S. Food and Drug Administration (FDA). Following multiple productive...

Read More

Neovasc Announces Second Quarter 2021 Financial Results

VANCOUVER and MINNEAPOLIS - (NewMediaWire) - August 10, 2021 - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), today reported financial results for the second quarter ended June 30, 2021.Second Quarter HighlightsGenerated revenue of approximately $633,000 in the quarter, up 123% from the...

Read More

Neovasc Announces New Appointments in Regulatory and Clinical Leadership

Neovasc Team Grows with Addition of Industry Veterans Lisa Becker as VP, Regulatory Affairs, Global Angina Therapies and Sarah Gallagher as VP of Clinical AffairsVANCOUVER and MINNEAPOLIS - (NewMediaWire) - July 13, 2021 - Neovasc Inc. (Neovasc or the Company) (Nasdaq, TSX: NVCN) announced today...

Read More

Neovasc Provides Corporate Update

VANCOUVER and MINNEAPOLIS - June 10, 2021 -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the Company has implemented a series of strategic initiatives focused on enhancing current shareholder value, minimizing dilution, extending its cash runaway well into 2024, focusing investments on near term...

Read More